CA1111453A - Polyether compounds, their production and their medicinal use - Google Patents

Polyether compounds, their production and their medicinal use

Info

Publication number: CA1111453A
Authority: CA; Canada
Prior art keywords: compound; process according; reaction; ethylene oxide; alkali metal
Prior art date: 1977-07-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA307,799A

Other languages

English (en)

French (fr)

Inventor

Gerd Steinert

Harald Horstmann

Rudiger Sitt

Hans P. Krause

Walter Puls

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer AG

Original Assignee

Bayer AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-07-21

Filing date

1978-07-20

Publication date

1981-10-27

1978-07-20 Application filed by Bayer AG filed Critical Bayer AG

1981-10-27 Application granted granted Critical

1981-10-27 Publication of CA1111453A publication Critical patent/CA1111453A/en

Status Expired legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 33
238000004519 manufacturing process Methods 0.000 title claims abstract description 6
229920000570 polyether Polymers 0.000 title abstract description 16
239000004721 Polyphenylene oxide Substances 0.000 title abstract description 12
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract description 18
238000000034 method Methods 0.000 claims abstract description 18
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims abstract description 12
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 26
238000006243 chemical reaction Methods 0.000 claims description 11
150000008044 alkali metal hydroxides Chemical class 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 5
238000001914 filtration Methods 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 4
229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
239000011707 mineral Substances 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
239000012442 inert solvent Substances 0.000 claims description 2
239000011541 reaction mixture Substances 0.000 claims description 2
229960004063 propylene glycol Drugs 0.000 claims 2
235000013772 propylene glycol Nutrition 0.000 claims 2
238000006386 neutralization reaction Methods 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 13
230000023852 carbohydrate metabolic process Effects 0.000 abstract description 2
235000021256 carbohydrate metabolism Nutrition 0.000 abstract description 2
230000004060 metabolic process Effects 0.000 abstract description 2
239000003085 diluting agent Substances 0.000 description 17
239000003814 drug Substances 0.000 description 17
239000008194 pharmaceutical composition Substances 0.000 description 16
229940117927 ethylene oxide Drugs 0.000 description 14
239000004480 active ingredient Substances 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
239000002775 capsule Substances 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
239000003826 tablet Substances 0.000 description 6
239000008298 dragée Substances 0.000 description 5
239000008187 granular material Substances 0.000 description 5
-1 paraffins Substances 0.000 description 5
239000006187 pill Substances 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000001427 coherent effect Effects 0.000 description 4
235000019441 ethanol Nutrition 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
235000012216 bentonite Nutrition 0.000 description 3
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
241000206672 Gelidium Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000001993 wax Substances 0.000 description 2
229940058015 1,3-butylene glycol Drugs 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000007792 addition Methods 0.000 description 1
230000000274 adsorptive effect Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229940093470 ethylene Drugs 0.000 description 1
239000010642 eucalyptus oil Substances 0.000 description 1
229940044949 eucalyptus oil Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000008141 laxative Substances 0.000 description 1
229940125722 laxative agent Drugs 0.000 description 1
230000002475 laxative effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000003605 opacifier Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
150000002924 oxiranes Chemical class 0.000 description 1
125000005702 oxyalkylene group Chemical group 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
239000002304 perfume Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
239000001120 potassium sulphate Substances 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000011701 zinc Substances 0.000 description 1
235000016804 zinc Nutrition 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
- C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
- C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
- C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Polymers & Plastics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Polyethers (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA307,799A 1977-07-21 1978-07-20 Polyether compounds, their production and their medicinal use Expired CA1111453A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19772732929 DE2732929A1 (de)	1977-07-21	1977-07-21	Polyaether, verfahren zu ihrer herstellung sowie ihre verwendung als lipidabsorptionshemmer
DEP2732929.9		1977-07-21

Publications (1)

Publication Number	Publication Date
CA1111453A true CA1111453A (en)	1981-10-27

Family

ID=6014492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA307,799A Expired CA1111453A (en)	1977-07-21	1978-07-20	Polyether compounds, their production and their medicinal use

Country Status (13)

Country	Link
EP (1)	EP0000704A1 (da)
JP (1)	JPS5422497A (da)
AU (1)	AU3806878A (da)
CA (1)	CA1111453A (da)
DE (1)	DE2732929A1 (da)
DK (1)	DK324678A (da)
ES (1)	ES471900A1 (da)
FI (1)	FI782284A7 (da)
IL (1)	IL55160A0 (da)
IT (1)	IT1097831B (da)
NO (1)	NO782332L (da)
PT (1)	PT68307A (da)
ZA (1)	ZA784129B (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6383500B1 (en)	1996-06-27	2002-05-07	Washington University	Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2850058A1 (de) *	1978-11-18	1980-05-29	Bayer Ag	Polyaether-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2916668A1 (de) *	1979-04-25	1980-11-13	Basf Ag	Formmassen, enthaltend styrolacrylnitril-copolymerisate und aethylenoxid-/pro- pylenoxid-dreiblockcopolymerisate, verwendung derselben und formteile aus solchen mischungen
JPS6030650B2 (ja)	1979-10-26	1985-07-17	日本油脂株式会社	座薬基剤組成物
DE3234084A1 (de) *	1982-09-14	1984-03-15	B. Braun Melsungen Ag, 3508 Melsungen	Pharmazeutische zubereitungen zur behandlung von unerwuenschten verwachsungen sowie deren verwendung
DE3420708C1 (de) *	1984-06-02	1985-07-18	Hoechst Ag, 6230 Frankfurt	Modifizierte Polyethylenglykole
WO1988006038A1 (en) *	1987-02-20	1988-08-25	Emory University	Antiinfective compounds and method of use
US5811088A (en) *	1987-02-20	1998-09-22	Emory University	Antiinfective compounds and methods of use
US5674911A (en) *	1987-02-20	1997-10-07	Cytrx Corporation	Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
EP0576612B1 (en)	1991-03-19	1999-12-01	Cytrx Corporation	Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
USRE38558E1 (en)	1991-03-19	2004-07-20	Cytrx Corporation	Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US7202225B1 (en)	1993-10-15	2007-04-10	Emanuele R Martin	Therapeutic delivery compositions and methods of use thereof
US6933286B2 (en)	1991-03-19	2005-08-23	R. Martin Emanuele	Therapeutic delivery compositions and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB610505A (en) *	1944-02-08	1948-10-18	Carbide & Carbon Chem Corp	A method for making polyoxyalkylene glycols
FR1116M (fr) *	1961-02-02	1962-02-12	Bernard Andre Francois Mirande	Utilisation de substances tensio-actives provenant de la condensation de l'oxyde d'éthylene sur les propylenes-glycols dans la résorption des oedemes locaux ou tissulaires systématisés.
ES334486A1 (es) *	1965-12-23	1967-11-01	Smith Kline & French Laboratories	Un procedimiento para la preparacion de una composicion farmaceutica que comprende la mezcla de un polimero de polioxipropileno-polioxietileno.

1977
- 1977-07-21 DE DE19772732929 patent/DE2732929A1/de active Pending
1978
- 1978-07-04 NO NO782332A patent/NO782332L/no unknown
- 1978-07-11 EP EP78100357A patent/EP0000704A1/de not_active Withdrawn
- 1978-07-17 AU AU38068/78A patent/AU3806878A/en active Pending
- 1978-07-17 PT PT68307A patent/PT68307A/pt unknown
- 1978-07-18 IL IL55160A patent/IL55160A0/xx unknown
- 1978-07-19 JP JP8721378A patent/JPS5422497A/ja active Pending
- 1978-07-19 FI FI782284A patent/FI782284A7/fi not_active Application Discontinuation
- 1978-07-19 IT IT25897/78A patent/IT1097831B/it active
- 1978-07-20 ES ES471900A patent/ES471900A1/es not_active Expired
- 1978-07-20 CA CA307,799A patent/CA1111453A/en not_active Expired
- 1978-07-20 ZA ZA00784129A patent/ZA784129B/xx unknown
- 1978-07-20 DK DK324678A patent/DK324678A/da unknown

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6383500B1 (en)	1996-06-27	2002-05-07	Washington University	Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6491903B1 (en)	1996-06-27	2002-12-10	Washington University	Particles comprising amphiphilic copolymers

Also Published As

Publication number	Publication date
DK324678A (da)	1979-01-22
IL55160A0 (en)	1978-09-29
IT7825897A0 (it)	1978-07-19
DE2732929A1 (de)	1979-02-01
JPS5422497A (en)	1979-02-20
FI782284A7 (fi)	1979-01-22
ES471900A1 (es)	1979-02-01
PT68307A (de)	1978-08-01
EP0000704A1 (de)	1979-02-21
NO782332L (no)	1979-01-23
AU3806878A (en)	1980-01-17
ZA784129B (en)	1979-07-25
IT1097831B (it)	1985-08-31

Legal Events

Date	Code	Title	Description
1998-10-27	MKEX	Expiry

Publication	Publication Date	Title
CA1149407A (en)	1983-07-05	Polyether compounds, their production and their medicinal use
AU752633B2 (en)	2002-09-26	Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
FI69449B (fi)	1985-10-31	Foerfarande foer framstaellning av farmakologiskt verksamma glseroldiestrar
SE445221B (sv)	1986-06-09	Fosfatet av 1-(2-hydroxietyl)-2-metyl-5-nitroimidazol och forfarande for framstellning av detta
IE51651B1 (en)	1987-02-04	Cerebral therapeutic agent and its use
US5190947A (en)	1993-03-02	Codeine salt of a substituted carboxylic acid, its use and pharmaceutical compositions thereof
EP0375350B1 (en)	1994-04-20	Cross-linked vinylpyridinium polymers
JP2001523228A (ja)	2001-11-20	求核性置換エクテイナシジン類およびｎ−オキシドエクテイナシジン類
NO782332L (no)	1979-01-23	Polyetere, fremgangsmaate til deres fremstilling samt deres anvendelse som lipidabsorbsjonshemmere
US6376682B1 (en)	2002-04-23	Compound with α-glucosidase inhibiting action and method for producing the same
US5273740A (en)	1993-12-28	Polystyrene anion exchange polymers
US6881744B2 (en)	2005-04-19	Carbinoxamine tannate
GB1564458A (en)	1980-04-10	Pharmaceutical compositions containing montmorillonite derivatives
US3202578A (en)	1965-08-24	Polymeric laxative composition and method of using same
CN101225042B (zh)	2012-05-30	亚贡二萜酸类化合物、药物组合物、制备方法及在制备治疗糖尿病药物中的应用
EP0068453A2 (en)	1983-01-05	Compositions for treating kidney stones
CN114246852B (zh)	2024-08-16	一种药物组合物在心脑血管疾病中的应用
WO1998017273A1 (en)	1998-04-30	Methods of using butyric acid or butyric acid derivatives to protect against hair loss
NZ272131A (en)	1996-11-26	4'- (and6-) raloxifene-beta-d-glucopyranoside derivatives and pharmaceutical compositions
CN110845559B (zh)	2023-02-28	新型喜树碱衍生物及其制备方法和应用
SE447896B (sv)	1986-12-22	Foreningar verksamma mot anti-rinovirus och forfarande for framstellning derav
RU2090205C1 (ru)	1997-09-20	Способ комплексной терапии заболеваний
EP0403198A2 (en)	1990-12-19	Compounds
US20050202050A1 (en)	2005-09-15	Single tank process for preparing tannate liquid and semi-solid dosage forms
US4332819A (en)	1982-06-01	Antiphlogistic agent and its use